<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223665</url>
  </required_header>
  <id_info>
    <org_study_id>30296</org_study_id>
    <secondary_id>973730AC06</secondary_id>
    <secondary_id>HSD 30296</secondary_id>
    <nct_id>NCT00223665</nct_id>
  </id_info>
  <brief_title>Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer</brief_title>
  <acronym>IAS</acronym>
  <official_title>A Prospective Study of Intermittent Androgen Suppression (IAS) in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a prospective analysis in men with localized prostate cancer who had rising
      Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
      Patients received Intermittent Androgen Suppression (IAS) in 9 month cycles until they became
      metastatic, became castrate resistant, or withdrew from the study. Subjects were monitored
      for time to development of Castration Resistant Prostate Cancer (CRPC) and overall survival.
      They were also monitored for the impact of IAS on a variety of neuro-psychiatric assessments
      and on bone density.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard first line treatment for men with early stage newly diagnosed localized prostate
      cancer is a surgical removal of the prostate, localized external beam radiation,
      brachytherapy, or a combination of surgery and radiation. In most patients Prostate Specific
      Antigen (PSA) levels will decline after these localized treatments, demonstrating a response
      to these therapies. However despite an initial response to localized treatment, some men will
      go on to later develop a rise in PSA levels, an indicator of Biochemical Relapsed Prostate
      Cancer (BRPC). For BRPC patients who have not yet developed metastasis, the standard
      treatment is Androgen Deprivation Therapy (ADT) to decrease levels of Testosterone,
      subsequently decreasing PSA levels. A low value for the PSA is more desirable as it may
      indicate no tumor growth.

      ADT may be administered as a continuous treatment (Continuous Androgen Suppression, or CAS)
      or as intermittent treatment (Intermittent Androgen Suppression, or IAS). This treatment is
      continued until the development of Castration Resistant Prostate Cancer (CRPC), indicated by
      a rise in PSA despite ADT. Giving the hormone therapy intermittently (in cycles of treatment
      and off treatment periods) appears to delay the change of prostate cancer to a type of
      prostate cancer that resists hormone therapy, prolonging efficacy of ADT monotherapy. IAS may
      also decrease the impact of ADT on mental status.

      This study evaluated the effect of intermittent androgen suppression on time to androgen
      independent progression (the development of castration resistant disease) and overall
      survival in men with localized prostate cancer. Subjects were also evaluated for the effects
      of intermittent androgen suppression on a variety of neuro-psychiatric assessments and on
      bone density.

      The subjects in this study had a rising PSA value after definitive therapy either with
      radical prostatectomy or external beam irradiation for the treatment of prostate cancer. All
      subjects were males at or over the age of 21 years.

      New subjects were introduced to this study protocol (along with other non-study treatment
      options) during a clinic visit with Dr. Higano or another sub-investigator. After informed
      consent was obtained, subjects underwent the following screening procedures before starting
      treatment: Bone density scan (DEXA), Technetium-99 bone scan, CT scan of the chest, abdomen,
      and pelvis, blood draw, and neuro-psychiatric assessments. Subjects then began androgen
      suppression with a two-week lead-in of Flutamide, followed by 9 monthly injections of
      Leuprolide Acetate. During the treatment, they had quarterly clinic visits and blood draws.
      Their PSA levels were monitored monthly, and if their PSA reached the appropriate nadir at by
      month 9, the androgen suppression was interrupted. At the end of each treatment cycle,
      subjects underwent another bone density test, blood draw, problem solving test, and
      neuro-psychiatric assessments.

      During the &quot;off treatment&quot; phase, the subject will again had quarterly clinic visits, blood
      draws, and neuro-psychiatric assessments. PSA and testosterone were be monitored monthly.
      Once the PSA reached the appropriate threshold, the subject performed another set of
      screening procedures and resumed treatment for another 9 months. This cycle continued until
      the patient withdrew from the study, was taken off the study due to toxicities or the
      decision of the investigator, or until the treatment with IAS was no longer effective in
      controlling the prostate cancer. The neuro-psychiatric assessments were only performed during
      the subject's first cycle of treatment (consisting of the 9 months on treatment, and at month
      3 of the off treatment period afterwards).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 1997</start_date>
  <completion_date type="Actual">September 6, 2012</completion_date>
  <primary_completion_date type="Actual">September 6, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects underwent androgen suppression with a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate. If PSA reached the appropriate nadir at by month 9, the androgen suppression was interrupted. Once the PSA reached the appropriate threshold, the subjects resumed treatment for another 9 months. These cycle continued until the patient withdrew from the study, was taken off the study due to toxicities or the decision of the investigator, or until the treatment with IAS was no longer effective in controlling the prostate cancer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Androgen Independence of Serum Prostate-Specific Antigen (PSA)</measure>
    <time_frame>From date of first treatment until the date of development of CR, metastatic progression, or study withdrawal, whichever came first, assessed up to 16 years.</time_frame>
    <description>Monthly Prostate-Specific Antigen (PSA) testing to assess the point at which each patient's disease stops responding to Androgen Deprivation Therapy (ADT). Androgen Independence (AI), also know as Castrate Resistance (CR), was defined as 2 serial rises in PSA while on ADT with Testosterone levels &lt;50 ng/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of IAS on Overall Survival.</measure>
    <time_frame>From date of first treatment until the date of death or study withdrawal, whichever came first, assessed up to 16 years.</time_frame>
    <description>Assessment of overall survival measured as median time from completion of first full cycle of IAS until date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Standardized Bone Mineral Density (BMD) of the Spine During IAS</measure>
    <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
    <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Standardized Bone Mineral Density (BMD) of the Left Hip During IAS</measure>
    <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
    <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health. Percent change was assess for each patient at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Osteopenia (Bone Loss) During IAS</measure>
    <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
    <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. This measure was defined as the percentage of participants with normal BMD scores at baseline who developed Osteopenia after the first cycle of ADT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Levels During IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Testosterone was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol Levels During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Estradiol was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Spatial Ability Test (Block Design) During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Spatial Ability was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Wechsler Adult Intelligence Scale-Revised, Block Design sub-test and measures participants' ability to analyze and construct abstract figures from their component parts. The test allows a time limit of 3 minutes per design, for a total of nine designs. Score is based on total number of designs completed (max 9, min 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Spatial Ability Test (Mental Rotation) During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Spatial Ability (Mental Rotation) was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Vandenberg &amp; Kuse (1978) Mental Rotation Test. Subjects are presented with line drawings of complex, three dimensional cubes on a computer screen. The subject must compare the two drawings and decide if they match. Score is based on number of correctly identified figures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Executive Function Testing (Stroop Task) During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Executive Function was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Stroop Color Word Interference Task. Subjects are asked to read 100 color words (red, green, blue), followed by identification of color blocks followed by reading the color of the ink and ignoring the word (e.g., the word 'blue' printed in green letters). Assessment was based on the amount of time needed to time to complete the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Verbal Memory Testing (Proactive Interference) During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via the Proactive Interference (PI) task. The PI task involves participants listening to a list of 10 words from the same semantic category (e.g., articles of clothing), and then recalling as many of these words as possible.The procedure is repeated for a total of 4 trials. Assessment is based on the total number of words recalled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Visual Working Memory Test During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Visual Working Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This task is based on the Subject Ordered Pointing Task (SOPT). The participant is shown a grid array of 10, 12 or 16 abstract designs and they must choose a new design with each refresh of the screen. Assessment is based on total number of errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Verbal Memory Testing (Story Recall) During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via Story Recall. This task is based on the well known Wechsler Memory Scale -Revised Logical Memory task. Participants listened to two brief narratives (stories) and were asked to recall as much as possible immediately after hearing each story and following a 20-minute delay. Assessment was based on number of correctly recalled pieces of information after a delay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Spatial Memory Testing During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Spatial Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT using the Puget Sound Route Learning Test. This test measured the ability to navigate a short route within a room. Three trials were administered followed by three trials of a new route using pictures placed on the floor as landmarks. A delayed recall is administered after twenty minutes. Performance was assessed based on number of correctly recalled sequences after a delay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Verbal Ability/Fluency Testing During First Cycle of IAS</measure>
    <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
    <description>Verbal Ability/Fluency was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. Participants were asked to verbally generate as many words beginning with a particular letter (e.g. P) within a 60 second period. Two trials were administered with two different letters. The total number of words generated was recorded for each letter and summed and analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intermittent Androgen Suppression (IAS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.
Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.</description>
    <arm_group_label>Intermittent Androgen Suppression (IAS)</arm_group_label>
    <other_name>Eulexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.</description>
    <arm_group_label>Intermittent Androgen Suppression (IAS)</arm_group_label>
    <other_name>Lupron Depot</other_name>
    <other_name>Eligard</other_name>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemical relapse (rising PSA) after initial treatment (radiation therapy,
             brachytherapy, or radical prostatectomy) for histologically or cytologically confirmed
             adenocarcinoma of the prostate

          -  Clinical stage A2, B, C, D1

          -  Age: older than 21 years old

          -  Performance status of 0 or 1

          -  Pretreatment serum testosterone, normal range (or no clinical evidence of testosterone
             deficiency).

          -  If less than 30 months since completion of radiation therapy, biopsy of prostate
             suggested within 6 months of study entry. If more than or equal to 30 months since
             completion of radiation therapy, biopsy of prostate suggested within 1 year.

          -  Written informed consent.

        Exclusion Criteria:

          -  Abnormal bone scan suggestive of metastatic osseous disease.

          -  Previous hormonal manipulation including orchiectomy or any medication with
             significant antiandrogenic activity (combined androgen suppression over 9 months,
             monotherapy antiandrogens, estrogens, ketoconazole). *Neoadjuvant androgen suppression
             therapy of less than or equal to 3 months is allowed, if this androgen suppression
             therapy was completed more than or equal to 1 year prior to study enrollment AND if
             the Testosterone level is within the normal ranges.

          -  Any systemic chemotherapy or curative radiotherapy within 6 months.

          -  Hepatic dysfunction:

               -  Total bilirubin greater than 2.0 mg/dl

               -  Aspartate transaminase (AST; SGOT) greater than 3 times the upper limit of normal
                  range

               -  Lactate dehydrogenase (LDH) greater than 3 times the upper limit of normal
                  range).

          -  Renal dysfunction:

               -  Blood urea nitrogen (BUN) greater than 40 mg/dl

               -  Serum Creatinine greater than 2.0 mg/dl.

          -  History or presence of other malignancy within the last 5 years (except treated
             squamous/basal cell carcinoma of the skin or superficial bladder carcinoma).

          -  Hypersensitivity to flutamide or leuprolide.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celestia Higano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>November 25, 2017</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Celestia Higano</investigator_full_name>
    <investigator_title>Professor, Medicine, Division of Oncology &amp; Urology</investigator_title>
  </responsible_party>
  <keyword>Intermittent Hormone Therapy</keyword>
  <keyword>Intermittent Androgen Suppression</keyword>
  <keyword>Biochemical Relapsed Prostate Cancer</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <keyword>Localized Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Flutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The target population for this trial was men with localized prostate cancer who had a rising PSA after definitive therapy (radiation therapy, brachytherapy, or radical prostatectomy). Patients were enrolled from Jan 1997 through Sept 2006 at the University of Washington and the Seattle Cancer Care Alliance.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intermittent Androgen Suppression (IAS)</title>
          <description>Intermittent Androgen Suppression in 9 month cycles:
Flutamide, 250 mg by mouth 3 times daily for a total of two weeks
Leuprolide Acetate, 7.5mg intramuscular injections every 4 weeks for a total of nine months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intermittent Androgen Suppression (IAS)</title>
          <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="60" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Androgen Independence of Serum Prostate-Specific Antigen (PSA)</title>
        <description>Monthly Prostate-Specific Antigen (PSA) testing to assess the point at which each patient's disease stops responding to Androgen Deprivation Therapy (ADT). Androgen Independence (AI), also know as Castrate Resistance (CR), was defined as 2 serial rises in PSA while on ADT with Testosterone levels &lt;50 ng/dL.</description>
        <time_frame>From date of first treatment until the date of development of CR, metastatic progression, or study withdrawal, whichever came first, assessed up to 16 years.</time_frame>
        <population>62 subjects were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), having a measurable treatment break afterwards, and having sufficient PSA measurements to assess androgen independence.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Androgen Independence of Serum Prostate-Specific Antigen (PSA)</title>
          <description>Monthly Prostate-Specific Antigen (PSA) testing to assess the point at which each patient's disease stops responding to Androgen Deprivation Therapy (ADT). Androgen Independence (AI), also know as Castrate Resistance (CR), was defined as 2 serial rises in PSA while on ADT with Testosterone levels &lt;50 ng/dL.</description>
          <population>62 subjects were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), having a measurable treatment break afterwards, and having sufficient PSA measurements to assess androgen independence.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.5" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of IAS on Overall Survival.</title>
        <description>Assessment of overall survival measured as median time from completion of first full cycle of IAS until date of death from any cause.</description>
        <time_frame>From date of first treatment until the date of death or study withdrawal, whichever came first, assessed up to 16 years.</time_frame>
        <population>62 subjects were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), having a measurable treatment break afterwards, and having sufficient data to assess survival status.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of IAS on Overall Survival.</title>
          <description>Assessment of overall survival measured as median time from completion of first full cycle of IAS until date of death from any cause.</description>
          <population>62 subjects were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), having a measurable treatment break afterwards, and having sufficient data to assess survival status.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.9" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Standardized Bone Mineral Density (BMD) of the Spine During IAS</title>
        <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point.</description>
        <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
        <population>56 subjects were evaluable for this outcome measure, defined as meeting all of the following: having completed first cycle of ADT (9 months); no prior or concurrent use of bisphosphonates; a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Standardized Bone Mineral Density (BMD) of the Spine During IAS</title>
          <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point.</description>
          <population>56 subjects were evaluable for this outcome measure, defined as meeting all of the following: having completed first cycle of ADT (9 months); no prior or concurrent use of bisphosphonates; a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2.</population>
          <units>Percent change in BMD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Cycle 1 versus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre Cycle 2 versus Post Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Standardized Bone Mineral Density (BMD) of the Left Hip During IAS</title>
        <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health. Percent change was assess for each patient at each time point.</description>
        <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
        <population>Out of 102 enrolled subjects, 56 were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), no prior or concurrent use of bisphosphonates, and a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Standardized Bone Mineral Density (BMD) of the Left Hip During IAS</title>
          <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health. Percent change was assess for each patient at each time point.</description>
          <population>Out of 102 enrolled subjects, 56 were evaluable for this outcome measure, defined as having completed first cycle of ADT (9 months), no prior or concurrent use of bisphosphonates, and a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2.</population>
          <units>Percent change of BMD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Cycle 1 versus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre Cycle 2 versus Post Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Osteopenia (Bone Loss) During IAS</title>
        <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. This measure was defined as the percentage of participants with normal BMD scores at baseline who developed Osteopenia after the first cycle of ADT.</description>
        <time_frame>From screening prior to first dose of ADT through the start of the second cycle of ADT.</time_frame>
        <population>38 subjects were evaluable for this outcome measure, defined as meeting all of the following: having completed first cycle of ADT (9 months); no prior or concurrent use of bisphosphonates; a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2; having baseline DEXA BMD within normal range at both spine and left hip.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Osteopenia (Bone Loss) During IAS</title>
          <description>Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. This measure was defined as the percentage of participants with normal BMD scores at baseline who developed Osteopenia after the first cycle of ADT.</description>
          <population>38 subjects were evaluable for this outcome measure, defined as meeting all of the following: having completed first cycle of ADT (9 months); no prior or concurrent use of bisphosphonates; a minimum of 3 DEXA scans: prior to cycle 1, after cycle 1, and prior to cycle 2; having baseline DEXA BMD within normal range at both spine and left hip.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone Levels During IAS</title>
        <description>Testosterone was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having testosterone measurements at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Levels During IAS</title>
          <description>Testosterone was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having testosterone measurements at each of the listed time points.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol Levels During First Cycle of IAS</title>
        <description>Estradiol was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having estradiol measurements at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol Levels During First Cycle of IAS</title>
          <description>Estradiol was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having estradiol measurements at each of the listed time points.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.60" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.12" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.76" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.35" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Spatial Ability Test (Block Design) During First Cycle of IAS</title>
        <description>Spatial Ability was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Wechsler Adult Intelligence Scale-Revised, Block Design sub-test and measures participants ability to analyze and construct abstract figures from their component parts. The test allows a time limit of 3 minutes per design, for a total of nine designs. Score is based on total number of designs completed (max 9, min 0).</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Androgen Blockade</title>
            <description>Intermittent Hormone Therapy using Flutamide and Leuprolide acetate
Flutamide: 250mg three times a day by mouth
Leuprolide Acetate: 7.5mg once a month by intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Spatial Ability Test (Block Design) During First Cycle of IAS</title>
          <description>Spatial Ability was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Wechsler Adult Intelligence Scale-Revised, Block Design sub-test and measures participants ability to analyze and construct abstract figures from their component parts. The test allows a time limit of 3 minutes per design, for a total of nine designs. Score is based on total number of designs completed (max 9, min 0).</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>Number of correctly completed designs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.47" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Spatial Ability Test (Mental Rotation) During First Cycle of IAS</title>
        <description>Spatial Ability (Mental Rotation) was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Vandenberg &amp; Kuse (1978) Mental Rotation Test. Subjects are presented with line drawings of complex, three dimensional cubes on a computer screen. The subject must compare the two drawings and decide if they match. Score is based on number of correctly identified figures.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Spatial Ability Test (Mental Rotation) During First Cycle of IAS</title>
          <description>Spatial Ability (Mental Rotation) was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Vandenberg &amp; Kuse (1978) Mental Rotation Test. Subjects are presented with line drawings of complex, three dimensional cubes on a computer screen. The subject must compare the two drawings and decide if they match. Score is based on number of correctly identified figures.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>Number of correctly identified figures</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.12" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.00" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.52" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Executive Function Testing (Stroop Task) During First Cycle of IAS</title>
        <description>Executive Function was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Stroop Color Word Interference Task. Subjects are asked to read 100 color words (red, green, blue), followed by identification of color blocks followed by reading the color of the ink and ignoring the word (e.g., the word blue printed in green letters). Assessment was based on the amount of time needed to time to complete the assessment.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Executive Function Testing (Stroop Task) During First Cycle of IAS</title>
          <description>Executive Function was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Stroop Color Word Interference Task. Subjects are asked to read 100 color words (red, green, blue), followed by identification of color blocks followed by reading the color of the ink and ignoring the word (e.g., the word blue printed in green letters). Assessment was based on the amount of time needed to time to complete the assessment.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>minutes to complete the assessment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.00" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.52" spread="22.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.58" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.82" spread="13.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Verbal Memory Testing (Proactive Interference) During First Cycle of IAS</title>
        <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via the Proactive Interference (PI) task. The PI task involves participants listening to a list of 10 words from the same semantic category (e.g., articles of clothing), and then recalling as many of these words as possible.The procedure is repeated for a total of 4 trials. Assessment is based on the total number of words recalled.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Verbal Memory Testing (Proactive Interference) During First Cycle of IAS</title>
          <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via the Proactive Interference (PI) task. The PI task involves participants listening to a list of 10 words from the same semantic category (e.g., articles of clothing), and then recalling as many of these words as possible.The procedure is repeated for a total of 4 trials. Assessment is based on the total number of words recalled.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>Number of correctly recalled words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.31" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.90" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.70" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.70" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Visual Working Memory Test During First Cycle of IAS</title>
        <description>Visual Working Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This task is based on the Subject Ordered Pointing Task (SOPT). The participant is shown a grid array of 10, 12 or 16 abstract designs and they must choose a new design with each refresh of the screen. Assessment is based on total number of errors.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Visual Working Memory Test During First Cycle of IAS</title>
          <description>Visual Working Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This task is based on the Subject Ordered Pointing Task (SOPT). The participant is shown a grid array of 10, 12 or 16 abstract designs and they must choose a new design with each refresh of the screen. Assessment is based on total number of errors.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>total number of errors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.22" spread="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.66" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.35" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Verbal Memory Testing (Story Recall) During First Cycle of IAS</title>
        <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via Story Recall. This task is based on the well known Wechsler Memory Scale Revised Logical Memory task. Participants listened to two brief narratives (stories) and were asked to recall as much as possible immediately after hearing each story and following a 20-minute delay. Assessment was based on number of correctly recalled pieces of information after a delay.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Verbal Memory Testing (Story Recall) During First Cycle of IAS</title>
          <description>Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via Story Recall. This task is based on the well known Wechsler Memory Scale Revised Logical Memory task. Participants listened to two brief narratives (stories) and were asked to recall as much as possible immediately after hearing each story and following a 20-minute delay. Assessment was based on number of correctly recalled pieces of information after a delay.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>number of correctly recalled data points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.06" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.86" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.38" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.16" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Spatial Memory Testing During First Cycle of IAS</title>
        <description>Spatial Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT using the Puget Sound Route Learning Test. This test measured the ability to navigate a short route within a room. Three trials were administered followed by three trials of a new route using pictures placed on the floor as landmarks. A delayed recall is administered after twenty minutes. Performance was assessed based on number of correctly recalled sequences after a delay.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Spatial Memory Testing During First Cycle of IAS</title>
          <description>Spatial Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT using the Puget Sound Route Learning Test. This test measured the ability to navigate a short route within a room. Three trials were administered followed by three trials of a new route using pictures placed on the floor as landmarks. A delayed recall is administered after twenty minutes. Performance was assessed based on number of correctly recalled sequences after a delay.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>number of correctly recalled sequences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.50" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.00" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.76" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.12" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score on Verbal Ability/Fluency Testing During First Cycle of IAS</title>
        <description>Verbal Ability/Fluency was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. Participants were asked to verbally generate as many words beginning with a particular letter (e.g. P) within a 60 second period. Two trials were administered with two different letters. The total number of words generated was recorded for each letter and summed and analyzed.</description>
        <time_frame>Baseline, Month 3, Month 9, and Month 12</time_frame>
        <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Androgen Suppression (IAS)</title>
            <description>Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.</description>
          </group>
        </group_list>
        <measure>
          <title>Score on Verbal Ability/Fluency Testing During First Cycle of IAS</title>
          <description>Verbal Ability/Fluency was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. Participants were asked to verbally generate as many words beginning with a particular letter (e.g. P) within a 60 second period. Two trials were administered with two different letters. The total number of words generated was recorded for each letter and summed and analyzed.</description>
          <population>Sub-population of 20 evaluable patients, defined as having completed first cycle of ADT (9 months), having at least a 3 month treatment break afterwards, and having these neuro-psychological assessments at each of the listed time points.</population>
          <units>Number of words generated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.65" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.15" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.29" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.70" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for each patient from the start of treatment until discontinuation from the study, an average of 16 years per patient.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combined Androgen Blockade</title>
          <description>Intermittent Hormone Therapy using Flutamide and Leuprolide acetate
Flutamide: 250mg three times a day by mouth
Leuprolide Acetate: 7.5mg once a month by intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular node ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>left hip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pnemonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="102" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="102" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="102" subjects_affected="14" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="102" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hyperlipidemia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>osteopenia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>pain, bone and muscle</sub_title>
                <counts group_id="E1" events="102" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="102" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="102" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>nocturia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="102" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Celestia Higano, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-606-1187</phone>
      <email>mjcampbe@seattlecca.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

